Onyvax Appoints J. Barrie Ward as Chairman

London, October 14, 2002 – Onyvax Ltd, a leading vaccine therapy company, today announced the appointment of Dr Barrie Ward as non-executive Chairman. Dr Ward brings more than 20 years of experience in the pharmaceutical and biotechnology industries.

Dr Ward is currently CEO of KuDOS Pharmaceuticals Ltd, which recently completed a $45m private financing. He also holds the position of Chairman of the Board at US-based Avant Immunotherapeutics. Dr Ward was previously Chairman and CEO of Virus Research Institute, Inc of Cambridge, MA, until its merger with T Cell Sciences to form Avant in 1998. Prior to that, he held divisional responsibility within Glaxo Research & Development. Dr Ward has a PhD in microbial biochemistry from the University of Bath.

Dr Ward commented, “I am delighted to join Onyvax at this exciting time, with Phase II trials of its lead product for prostate cancer well underway. The Company has established firm foundations and gained a strong position in regulatory affairs and the development of biologics through its clinical trials programme. I look forward to working with its proven management team and Board of Directors.”

Dr Ward replaces Barrie S. Haigh, who held the position of Onyvax Chairman for five years and is now stepping down to concentrate on other business activities.

Mr Haigh said, “Onyvax has achieved remarkable progress since its inception and has earned a leadership position in cancer immunotherapy and biologics. At this pivotal stage in the Company’s growth, it is appropriate to bring on board a seasoned and respected individual with proven achievements in big pharma and biotech on both sides of the Atlantic. I believe the Company is well positioned for growth, both through its innovative internal R&D and external alliances. ”